Evidence map›Paper›PMID 35715880›Full record

ReviewCancer reports (Hoboken, N.J.)2022

Lenvatinib in multimodal therapy for unresectable radioactive iodine-naïve differentiated thyroid cancer: A case report with literature review.

Hugh Andrew Jinwook Kim, Anthony Charles Nichols, Ramanamurthy Rachakonda, Richard Inculet, Jinka Sathya, Irina Rachinsky, Eric Winquist

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer reports (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hugh Andrew Jinwook KimSchulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.ORCID 0000-0002-8424-148X
Anthony Charles NicholsDepartment of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Canada.ORCID 0000-0002-0760-980X
Ramanamurthy RachakondaDepartment of Radiation Oncology, Grand River Regional Cancer Centre, Kitchener, Canada.
Richard InculetDivision of Thoracic Surgery, Department of Surgery, University of Western Ontario, London, Canada.
Jinka SathyaDivision of Radiation Oncology, Department of Oncology, University of Western Ontario, London, Canada.
Irina RachinskyDepartment of Medical Imaging, University of Western Ontario, London, Canada.
Eric WinquistDivision of Medical Oncology, Department of Oncology, University of Western Ontario, London, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with unresectable or metastatic differentiated thyroid carcinoma (DTC) are rare and require individualized therapy. This may require approaches not typically used in resectable disease. We report a patient treated with lenvatinib and external beam radiation therapy. CASE: An 87-year-old woman presented with cT4N1aM1 papillary thyroid carcinoma with tracheal invasion. She was not a candidate for surgery, radioactive-iodine, or radiation, so a trial of lenvatinib was offered. Her tumor showed clinical, biochemical, and radiological response after 5 months of lenvatinib, and she subsequently received external beam radiation. She enjoys good quality of life without evidence of cancer progression off therapy 21 months post-initiation of treatment.

conclusionLenvatinib may be effective in RAI-naïve advanced DTC patients as a component of individualized multimodal therapy when conventional options are not feasible.

Indexed as

AdenocarcinomaAntineoplastic AgentsThyroid NeoplasmsAged, 80 and overFemaleHumansIodine RadioisotopesPhenylurea CompoundsQuality of LifeQuinolinesAntineoplastic AgentsIodine RadioisotopeslenvatinibPhenylurea CompoundsQuinolinescancer carecancer managementcancer medicineclinical observationshead and neck cancerimmunotherapy

Identifiers

PMID35715880
PMCPMC9575506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.